Bioceltix S.A.

zł 69.00As of Sun 8 Nov 2026, 12:00 UTC
WSE:BCXHealthcare
Country Poland
PE (Fwd) •••
TSR 5Y CAGR 13.77%
Div yield —
ROE (39.44%)
Biotechnology
Beta (5Y) 0.93
PE TTM —
TSR TTM (28.87%)
Mkt cap zł 381.7M
ROIC (24.58%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
zł 67
(3.11%)
(50.65%)
Hold 8|0|2|1|6
4Q25
1Q26
2Q26
3Q26
Earnings per sharezł
0.92
1.01
1.01
1.12
14.92%
15.40%
14.34%
17.41%
Revenuezł M
37.50
38.98
39.59
40.16
6.61%
9.99%
6.95%
9.80%
Peers (US$96.40M)
Cap (US$)
PE
75.03M
—
Capital
TTM
5Y
10Y
Leveragex
0.621
2.452
1.618
EBIT/Intx
0.455
0.040
0.042
Own earn%
(61.94)
108.16
92.39
Sh yield%
23.58
37.79
33.72
Owners
Insiders/Inst%
8.13
53.87
Short interest%
0.55
SBC / revenue%
2.50
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
12
Op margin range%
17–23
$1 testx
−0.1
Incr. ROIC%
3